Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of…
Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira,…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…